A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry

Biomedical Chromatography

Volumn 28, Issue 2, 2014, Pages 197-203

  Qin, Chong Zhen ^a   Ren, Xian ^b   Tan, Zhi Rong ^a   Chen, Yao ^a   Yin, Ji Ye ^a   Yu, Jing ^a   Qu, Jian ^a   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a Central South University   (China)

^b Shanghai PharmValley Corp   (China)

Author keywords

Cocktail; Cytochrome P450; Drug drug interactions; High throughput; Liquid chromatography mass spectrometry

Indexed keywords

BIOMOLECULES; CONTROLLED DRUG DELIVERY; DRUG INTERACTIONS; ENZYME INHIBITION; MASS SPECTROMETRY; QUALITY CONTROL; THROUGHPUT;

7-HYDROXYCOUMARIN; COCKTAIL; CYTOCHROME P450 ENZYMES; CYTOCHROMES P450; DRUG-DRUG INTERACTIONS; HIGH-THROUGHPUT; HUMAN CYTOCHROMES P450; IN-VITRO; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY;

METABOLITES;

4' HYDROXYMEPHENYTOIN; ALPHA HYDROXYMETOPROLOL; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450; HYDROXYTOLBUTAMIDE; TRAMADOL; UMBELLIFERONE; WATER;

ACCURACY; ARTICLE; HUMAN; IC 50; IN VITRO STUDY; INCUBATION TIME; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

COCKTAIL; CYTOCHROME P450; DRUG-DRUG INTERACTIONS; HIGH-THROUGHPUT; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME ASSAYS; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84892371509     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3003     Document Type: Article

References (38)

1. Atkinson A, Kenny JR and Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metabolism and Disposition 2005; 33: 1637-1647.
2. Ayrton J, Plumb R, Leavens WJ, Mallett D, Dickins M and Dear GJ. Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Communications in Mass Spectrometry 1998; 12: 217-224.
3. Bertz RJ and Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics 1997; 32: 210-258.
4. Bhoopathy S, Xin B, Unger SE and Karnes HT. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes. Journal of Pharmacy and Biomedical Analysis 2005; 37: 739-749.
5. Bu HZ, Magis L, Knuth K and Teitelbaum P. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites. Rapid Communications in Mass Spectrometry 2000; 14: 1619-1624.
6. Bu HZ, Magis L, Knuth K and Teitelbaum P. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Communications in Mass Spectrometry 2001; 15: 741-748.
7. Crespi CL, Miller VP and Penman BW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analytical Biochemistry 1997; 248: 188-190.
8. De Bock L, Vande CS, Mulliez SM, Boussery K and Van Bocxlaer JF. In vitro cytochrome P450 activity: development and validation of a sensitive high performance liquid chromatography-tandem mass spectrometry method for the quantification of six probe metabolites after derivatization with pyridine-3-sulfonyl chloride in an aqueous environment. Journal of Chromatography. A 2011; 1218: 793-801.
9. De Bock L, Boussery K, Colin P, De Smet J, T'Jollyn H and Van Bocxlaer J. Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity. Talanta 2012; 89: 209-216.
10. Di L, Kerns EH, Li SQ and Carter GT. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. International Journal of Pharmacy 2007; 335: 1-11.
11. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H and Ball SE. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism and Disposition 2001; 29: 23-29.
12. Gomez-Lechon MJ, Castell JV and Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opinion on Drug Metabolism and Toxicology 2008; 4: 837-854.
13. He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, Zhao LZ, Chen X and Huang M. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Communications in Mass Spectrometry 2007; 21: 635-643.
14. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH and Shin JG. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2005; 19: 2651-2658.
15. Lahoz A, Donato MT, Castell JV and Gomez-Lechon MJ. Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. Current Drug Metabolism 2008; 9: 12-19.
16. Li X, Chen X, Li Q, Wang L and Zhong D. Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007; 852: 128-137.
17. Liu KH, Lee YM, Shon JH, Kim MJ, Lee SS, Yoon YR, Cha IJ and Shin JG. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica 2004; 34: 429-438.
18. Moody GC, Griffin SJ, Mather AN, McGinnity DF and Riley RJ. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 1999; 29: 53-75.
19. Otten JN, Hingorani GP, Hartley DP, Kragerud SD and Franklin RB. An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS. Drug Metabolism Letters 2011; 5: 17-24.
20. Pelkonen O, Turpeinen M, Uusitalo J, Rautio A and Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic and Clinical Pharmacology & Toxicology 2005; 96: 167-175.
21. Peng SX, Barbone AG and Ritchie DM. High-throughput cytochrome p450 inhibition assays by ultrafast gradient liquid chromatography with tandem mass spectrometry using monolithic columns. Rapid Communications in Mass Spectrometry 2003; 17: 509-518.
22. Shader RI, Granda BW, von Moltke LL, Giancarlo GM and Greenblatt DJ. Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharmacy and Drug Disposition 1999; 20: 385-388.
23. Smith D, Sadagopan N, Zientek M, Reddy A and Cohen L. Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007; 850: 455-463.
24. Taavitsainen P, Juvonen R and Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabolism and Disposition 2001; 29: 217-222.
25. Testino SJ and Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. Journal of Pharmacy and Biomedical Analysis 2003; 30: 1459-1467.
26. Turpeinen M, Uusitalo J, Jalonen J and Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. European Journal of Pharmaceutical Science 2005; 24: 123-132.
27. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
28. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
29. Walsky RL and Obach RS. Validated assays for human cytochrome P450 activities. Drug Metabolism and Disposition 2004; 32: 647-660.
30. Wienkers LC and Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews Drug Discovery 2005; 4: 825-833.
31. Yan Z and Caldwell GW. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Current Topics in Medical Chemistry 2001; 1: 403-425.
32. Yao M, Zhu M, Sinz MW, Zhang H, Humphreys WG, Rodrigues AD and Dai R. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. Journal of Pharmacy and Biomedical Analysis 2007; 44: 211-223.
33. Yin H, Racha J, Li SY, Olejnik N, Satoh H and Moore D. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica 2000; 30: 141-154.
34. Youdim KA, Lyons R, Payne L, Jones BC and Saunders K. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. Journal of Pharmacy and Biomedical Analysis 2008; 48: 92-99.
35. Zambon S, Fontana S and Kajbaf M. Evaluation of cytochrome P450 inhibition assays using human liver microsomes by a cassette analysis /LC-MS/MS. Drug Metabolism Letters 2010; 4: 120-128.
36. Zhang L, Wei MJ, Zhao CY and Qi HM. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacologica Sinica 2008; 29: 1507-1514.
37. Zhang T, Zhu Y and Gunaratna C. Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2002; 780: 371-379.
38. Zientek M, Miller H, Smith D, Dunklee MB, Heinle L, Thurston A, Lee C, Hyland R, Fahmi O and Burdette D. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. Journal of Pharmacological and Toxicological Methods 2008; 58: 206-214.